Plasma volume status in type 2 diabetes and its association with antidiabetic therapy
Main finding · PVSResult — go to the resultMean difference + 3.73 % 95% CI 0.24–7.22Authors' conclusion
T2D is associated with a modest but significant increase in PVS. Among antidiabetic agents, SGLT2 inhibitors -alone or in combination with GLP-1 RA- were associated with a contraction in PVS, suggesting favourable hemodynamic effects. Conversely, DPP4 inhibitors were linked to more expanded plasma volume. These findings highlight the differential hemodynamic impact of glucose-lowering therapies and support further prospective research to evaluate their role in cardiovascular protection in T2D.
Study context
- Population
- Adults with T2D and matched healthy controls; separate larger T2D cohort for antidiabetic therapy analysisT2D cohort n = 638
- Exposure
- T2D vs healthy controls; antidiabetic therapies vs diet/metformin within T2D
- Outcome
- PVS
Methodological detailsmatched for sex, age and BMI
- Matched for sex, age and BMI
Main finding
As reported in the abstract
Mean difference
+ 3.73 %
95% CI 0.24–7.22
P = 0.041
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| PVS by antidiabetic therapy within T2D cohortSGLT2 inhibitors vs Diet/metformin · lower PVS with SGLT2 inhibitors · diet/metformin reference group | mean difference - 3.40 % (95% CI - 6.14 to - 0.66) | P = 0.015 |
| PVS by antidiabetic therapy within T2D cohortSGLT2i + GLP-1RA · greatest reduction · diet/metformin reference group | −6.50 % (95% CI - 12.25 to −0.75) | P = 0.004 |
| PVS by antidiabetic therapy within T2D cohortGLP-1RA · non-significant lower PVS · diet/metformin reference group | −2.10 % (95% CI - 5.48 to 1.28) | |
| PVS by antidiabetic therapy within T2D cohortDPP-4 inhibitors · significantly higher PVS · diet/metformin reference group | + 4.15 % (95% CI + 0.05 to + 8.85) | P = 0.008 |
- Plasma Volume Status (PVS) by antidiabetic therapy within T2D cohort: T2D cohort n = 638
PVS by antidiabetic therapy within T2D cohort
- No significant difference in PVS between insulin-treated individuals and those on diet/metformin
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →